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Abstract
Background: Choroid plexus carcinomas (CPC) are rare tumors predominantly found in children. Given the high frequency
of the germline R337H mutation in the TP53 gene in southern Brazil, we have evaluated the frequency of the R337H
mutation in families with CPC in children.
Methodology/Principal Findings: The present series included 29 patients that were admitted to the same institution from
1992 to 2010, including 22 children with CPC (0.08–13.6 years of age at diagnosis) and 7 children with papilloma of the
choroid plexus (Pp; 0.5–9.8 years of age). Surgical resection was possible in 28 children. Blood and/or tumor DNA was
extracted and analyzed using PCR-RFLP and results were confirmed by sequencing 240 bp of the TP53 exon 10. The
patients, all parents, and some relatives submitted samples for blood DNA analysis. In addition, we have also examined the
presence of the mutation in DNA from paraffin-embedded tumor samples to evaluate loss of heterozygosity. We found
63.3% (14/22) of the CPC patients positive for the germline R337H mutation; CPC samples were either heterozygous (n=7),
lost only the wild-type (n=4), or only the R337H copy (n=2). One CPC sample was not available. All Pp cases (7/7, 100%)
were negative for R337H. Cure (.5 years survival free of disease) was observed in 18.1% of the CPC cases with the R337H
mutation (2/11), 71.4% of the Pp (5/7), and 25% of CPC cases negative for the R337H mutation (2/8). Family history of cancer
(with 2 or more cancer cases) was exclusively identified on the parental side segregating the R337H mutation, and 50% (7/
14) of them were compatible with Li-Fraumeni-like syndrome.
Significance: Our results show for the first time that the R337H TP53 mutation is responsible for 63% of the CPC cases in
children, suggesting a higher incidence of CPC in southern Brazil.
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Introduction
Choroid plexus carcinomas (CPC) are tumors originated from
the epithelium lining the brain ventricles, and are typically found
in children. CPC corresponds to 1–4% of all pediatric intracranial
tumors [1] and are much less common than the benign
intraventricular papillomas (Pp) [2]. CPC are very aggressive
tumors, with a very unfavorable prognosis and typically appear in
the first decade of life (38% of cases) [3]. The relatively small
number of CPC cases in the literature, coupled with the lack of
relevant epidemiological data and controversies about their
clinical and pathological diagnosis makes it difficult to establish a
standardized therapeutic approach in managing this condition
[4,5]. Considering the high mortality rate for CPC, it is very
important to identify biologic markers that may be relevant to
understanding risk stratification, tumor formation mechanism, and
prognosis [6]. The most common mechanism involved in CPC
formation is related to dysfunction in the tumor suppressor p53,
more frequently found in families with Li-Fraumeni syndrome
(LFS). It was recently reported that 50% of the patients with CPC
were positive for germline TP53 mutation [7]. These authors have
concluded that children with CPC who have a p53 protein with
low total structural variation and absence of TP53 dysfunction
have a favorable prognosis and can be successfully treated without
radiation therapy.
Twenty four of the 29 cases included in the present study (24/
29, 82.7%) were investigated in a previous histopathologic
analysis claiming increased incidence of CPC in the state of
Parana ´, Brazil due to an unknown pathogen [8]. The present
study was designed to address the question whether the
increased number of CPC cases proposed in this previous study
was related to the high frequency of the R337H germline
mutation in southern Brazil [9,10]. This mutation produces a
10–15 times higher adrenocortical tumor (ACT) incidence in
southern Brazil than in the United States [11]. CPC is as rare as
ACT in the United States, both occurring with an incidence of
0.3 per million of children younger than 15 years of age
[2,12,13,14].
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Subjects
This study and the written consent form were approved by the
Pequeno Prı ´ncipe Hospital Ethics Committee and the Federal IRB
(CONEP, Brasilia, DF, Brazil). With approval and participation
by their parents, samples (blood and/or tumor DNA) were
collected from children admitted between 1992 and 2010 at
Pequeno Prı ´ncipe Hospital (Curitiba, Brazil) and additional blood
samples were obtained from some of their relatives after signing
the consent form. A total of 22 cases of CPC from 15 boys and 7
girls, and 7 Pp from 4 girls and 3 boys were screened for the
R337H mutation in the TP53 gene. Histopathology was re-
evaluated, and clinical and pedigree analyses were obtained.
Involvement of one or both lateral ventricles was observed in all
cases of CPC and Pp. The clinical manifestations were similar, and
in most cases intracranial hypertension and/or hydrocephalus
were observed. Surgical treatment was possible in 28 of the 29
patients and it was the only treatment for Pp. The protocol for
chemotherapy (cisplatin and carboplatin) was similar for all
patients with CPC. Five of the CPC patients were submitted to
radiotherapy.
Pedigree analysis and family history of cancer
One drop of blood was obtained (pricking of finger for subjects
older than 3 years of age, or heel prick for children younger than 3
years). The blood drop was stored in DNA Cards (MGM,
Curitiba, Brazil). Pedigrees and histories of cancer were obtained
from each side of the family.
PCR-RFLP assay
Two 2 mm punches of the DNA card from each sample were
used 1–2 weeks later in the assay. Within this time period, it was
sufficient to wash twice with washing solution (MGM Assessoria
Biolo ´gica, Curitiba, Parana ´) for 5 min at 37uC, and twice in
autoclaved double distilled water (ddH2O) for 3 min. Punches
were dried at 60uC for 15 min and stored at 220uC until used in
PCR assays as previously described [9]. PCR was carried out in a
50 ml PCR buffer containing 2.5 U platinum Taq polymerase
(Invitrogen, USA), 100 pmol of forward and reverse primers,
25 nmol each of deoxy-NTPs (Invitrogen) and 20–30 ng genomic
DNA. The 447 base pair (bp) PCR product corresponding to a
fragment of TP53 exon 10 was generated using the following
primers: 59-CTG AGG CAC AAG AAT CAC-39 (forward) and
59-TCC TAT GGC TTT CCA ACC-39 (reverse). Samples were
denatured at 95uC for 45 seconds and amplified by 30 cycles
(annealing at 62uC for 45 seconds and primer extension at 72uC
for 45 seconds). The amplified product was digested with Hha1,
yielding 293 bp and 154 bp fragments in 1.8% agarose gel, if the
R337H point mutation was not present.
Genomic DNA from formalin-fixed and paraffin-embedded
tumor tissue (FF-PET) samples were isolated using a protocol
modified from Farrugia et al. [15]. Three 5-mM thick FF-PET
sections from representative areas of tumor, avoiding necrosis and
normal tissue (tissue block measuring 5 mm 65 mm) were
incubated in 1 mL autoclaved ddH2O at 70uC for 20 min,
centrifuged for 3 min and the liquid with melted paraffin was
discarded. This procedure was repeated twice. The tissues were
incubated with proteinase K in lysis buffer overnight and the next
steps were performed using a commercial kit for paraffin-
embedded tissue (Qiagen). Part of the exon 10 of the TP53 gene
(240 kb) was amplified using polymerase chain reaction (PCR)
using standard protocols. Approximately 30–50 ng of micro-
dissected tumor genomic DNA was used in the PCR-RFLP assay.
PCR-RFLP for DNA extracted from FF-PET was performed with
some modifications: forward primer was replaced by 59-TAA
CTT GAA CCA TCT TTT AAC TC-39, the annealing
temperature was reduced to 61uC, electrophoresis was performed
in 3% agarose gel for 70 min (10 min longer). The wild-type
amplicon (240 bp) digested with Hha1 yielded two fragments (85
and 160 bp). All cases identified with the R337H mutation were
confirmed by sequencing the amplified 240 bp of exon 10.
Statistical analysis
Progression-free survival rate for tumors positive for the
germline mutation was compared with those negative for the
mutation by using the Kaplan-Meier method. Chi-square test or
Fisher’s Exact Test were applied to compare categorical variables
among the groups. The Kruskal-Wallis non-parametric test was
used to compare continuous variables. A P value ,0.05 was
considered significant.
Results
Fourteen children with CPC (14/22, 63.6%) were identified
with the germline R337H TP53 mutation (Table 1). This mutation
was confirmed in blood DNA from at least one of the parents
(n=14) and in other members of the families (33 out of 115 tested
individuals), ruling out a de novo mutation. Only 9 relatives of these
children who had other types of cancer were tested and were
found to be carriers of the R337H mutation (9/9). Loss of
heterozygosity (LOH) was found in 46.1% (6/13) of the CPC
cases, including 4 CPC with loss of the wild-type TP53 and 2 with
loss of the R337H haplotype, while the remaining available CPC
(n=7) were heterozygous (Table 1).
Figure 1 presents three pedigrees with an example for each
situation: only one single 240 bp band depicting loss of the wild-
type (Fig. 1A, shown in lane 2: PCR product from CPC DNA
treated with HhaI, in contrast to the lane 3 profile with PCR
product from the patient’s blood DNA treated with HhaI), only
two smaller bands, 80 bp and 160 bp, illustrating absence of the
R337H copy (Fig. 1B, shown in lane 2: PCR product from
patient’s CPC DNA treated with HhaI, in contrast to the lane 3
profile with PCR product from his father’s blood DNA treated
with HhaI) and the heterozygous pattern with all three bands
(Fig. 1C, shown in lane 2: PCR product from patient’s CPC DNA
treated with HhaI). All cases were confirmed by DNA sequencing
of the patient or parental blood DNA, or in DNA from normal
brain tissue surrounding CPC.
Age, gender, outcome, and family history of cancer are shown
for CPC with the mutation (Table 1) and for CPC and Pp without
the R337H mutation in the TP53 gene (Table 2). Survival rate (.5
years free of disease) was not significantly different among patients
with CPC and the mutation (2/11, 18.1%), CPC patients without
the mutation (2/8, 25%) and patients with Pp without the
mutation (5/7, 71.4%) probably due to the small number of cases.
If we consider all CPC patients together (n=22) and compare with
Pp patients, the difference in survival is also not statistically
significant.
The pedigrees of the 14 families with the germline mutation
were obtained together with the history of cancer reported by both
sides of the families; ipsilateral and contralateral to the parental
side segregating the R337H mutation (Table 1). The total number
of relatives with cancer in families with the germline R337H
mutation (n=51) was significantly higher than in the contralateral
side of the family (n=4) or in any side of the families of CPC
patients without the mutation (n=10) or with Pp patients (n=7).
The tumor types reported by all families revealed that the most
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9.0%), prostate (n=6, 9.0%) and ACT (n=6, 9.0%) in families
with CPC and the R337H mutation. None of the families
presented classic LFS. However, LFS-like syndrome (LFL) as
defined by Birch et al. [16], was identified in 7 of the 14 families
with the R337H mutation (50%), and in 6 of the 14 families with
the R337H mutation (42.8%) according to Tinat et al. [17]. None
of the families contralateral to the parental side segregating the
R337H mutation presented LFL. History of cancer in the families
negative for the R337H mutation, presented LFL only in one
family with CPC without the R337H mutation and none in
families with Pp.
Discussion
Although none of the families can be classified as LFS, LFL was
clearly associated with the parental side segregating the R337H
mutation. According to Aguzzi et al. [2], CPC affects more boys
than girls (ratio 3:1), which is consistent with the present series of
cases (15 boys and 7 girls). It was previously described that CPC
represented 63.2% of all choroid plexus tumors in Curitiba, Brazil
[8], in contrast to 8.1% (4) and 16.6% [2] in other series. This
unusual higher proportion of CPC cases found in Curitiba was
hypothesized to be related to an unknown pathogen [8].
This increased incidence of CPC can be accounted for by the
presence of the TP53 R337H germline mutation in the population
of Parana ´. It was previously described the germline R337H
mutation in 35 of 36 children with adrenocortical cancer (ACC)
using a GeneChip p53 probe array (Affymetrix, Santa Clara, CA)
and sequence analysis of the TP53 coding sequence and no other
TP53 mutations were detected [9]. The hemizygous pattern with
the R337H haplotype, after loss of the wild type TP53 found in 4/
14 CPC cases, reinforces the idea that the R337H protein is
defective and may under certain metabolic conditions lose its
protective role against cancer formation [18]. Remarkably,
permanence of the wild-type allele in most CPC (9/13), including
loss of the R337H copy (n=2), challenge the general assumption
that the tumor suppressor activity for TP53 must be inactivated in
the tumor. However, although the tumor tissue was carefully
dissected, we cannot rule out the possibility of contamination with
normal brain cells in the analyzed samples. It was previously found
100% of LOH (loss of the wild-type allele) in childhood
adrenocortical cancer with the R337H germ-line mutation
[9,10], which is consistent with the classical two-hit mechanism
of cancer proposed by Knudson [19]. In contrast, other studies
have shown lower frequency of LOH (60–78%) in the same type of
tumor with R337H [29,30]. Furthermore, LOH was described in
3 cases of breast cancer, including loss of the mutant R337H and
permanence of the wild-type TP53 allele [20]. Conversely, in all
families described in the present study the pedigrees show that the
cancer cases are clearly associated with the R337H allele in one
parental side, which reduces the remote possibility of a second
mutation in the second copy of the TP53 gene in the contralateral
side of the families (negative for R337H), because none of them
presented either LFS or LFL cancer history.
Functional analysis of the R337H p53 protein was previously
performed using two cell types devoid of endogenous p53.
Immortal murine BALB/c fibroblasts were used for promoter
transactivation studies and human SaOS-2 osteosarcoma cells for
colony reduction assays. The R337H mutant activated the
Table 1. Survival and history of cancer in the families of children with CPC carrying the R337H mutation.
Patient
Gender/Age
(years) Treatment Outcome Histopathology
Blood DNA
R337H
Tumor DNA
R337H Family history of cancer
IPSI CONTRA
nn
1 F/13.6 - Deceased CPC R337H/Wt*** NA 4 0
2 M/1.8 CSR/Ct Deceased CPC R337H/Wt R337H/- NA 1
3 M/2.5 CSR/Ct Deceased CPC R337H/Wt -/Wt 1 1
4 F/0.4 CSR/Ct Deceased CPC R337H/Wt -/Wt 4 0
5 M/11 CSR/Ct Deceased CPC R337H/Wt R337H/Wt 4 0
6 M/0.9 CSR/Ct Alive CPC R337H/Wt R337H/Wt 3 0
7 M/2.3 CSR/Ct Deceased CPC R337H/Wt R337H/Wt 7 NA
8 M/6.6 CSR/Ct Deceased CPC R337H/Wt R337H/Wt 4 1
9 M/2.9 CSR/Ct Alive CPC R337H/Wt R337H/Wt 8 0
10 M/1.2 CSR/Ct Deceased CPC R337H/Wt R337H/Wt 2 1
11 F/5.9 CSR/Ct Alive* CPC R337H/Wt R337H/- 0 NA
12 F/0.9 CSR/Ct Deceased CPC R337H/Wt R337H/Wt 3 NA
13 M/4 CSR/Ct Alive* CPC R337H/Wt R337H/- 5 0
14 M/0.08 CSR/Ct Alive* CPC R337H/Wt R337H/- 6 NA
Total 14 13 13 51 4
Survival rate** 2/11 (18.1%)
CSR, Complete surgical removal; Ct, Chemotherapy; NA, Not available.
*,5 years free of disease;
**.5 years free of disease;
***DNA analysis estimated from their parents.
The number of cancer cases in each family was shown in the IPSI (ipsilateral) and CONTRA (contralateral) to the parental side segregating the R337H mutation.
doi:10.1371/journal.pone.0018015.t001
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p53 and the R337H mutant were able to suppress colony growth
of SaOS-2 cells [9]. One year later, DiGiammarino et al. [18],
demonstrated that a pH-sensitive molecular defect of p53 (R337H)
leading to diminished p53 tetramerization is the molecular basis
for these cases of ACC in Brazilian children. They have also
Figure 1. Typical pedigrees. The pedigrees of families with the germline TP53 R337H mutation illustrate three different patterns of allele
combinations shown in the digital photos of the gel, with loss of the wt allele in A (lane 1: DNA ladder; lane 2: PCR product from CPC DNA treated
with HhaI and lane 3 with PCR product from the patient’s blood DNA treated with HhaI), loss of the R337H copy in B (lane 1: DNA ladder; lane 2: PCR
product from CPC DNA treated with HhaI and lane 3 with PCR product from the father’s blood DNA treated with HhaI), and without any loss shown in
C (lane 1: DNA ladder; lane 2: PCR product from CPC DNA treated with HhaI and lane 3 with PCR product from the patient’s blood DNA treated with
HhaI).
doi:10.1371/journal.pone.0018015.g001
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R337H function.
Considering that this peculiar TP53 mutation is present in
similar frequency in other states of southern Brazil, it is likely that
the actual number of CPC in children caused by R337H per year
is higher than the previously reported 0.3 per million incidence
[1]. The population size in two states (Parana ´ and Sa ˜o Paulo), with
50 million inhabitants, including approximately 15 million
children younger than 15 years of age, represents a serious public
health concern. In a series of 31 families carrying the germline
R337H mutation and 41 cases of ACT, none of them presented
any case of CPC [10]. Most of the ACT in children reported to
date in southern Brazil (85–95%) present the germline R337H
mutation [11]. In addition, the total number of childhood ACT
admitted to the main hospitals in the state of Parana ´ is much
higher than the total number of children admitted with CPC.
These observations are consistent with a lower R337H penetrance
for CPC than for ACT in Brazilian children in these areas.
In a previous study, we had found LFL in only 23.3% of the
families (7/30) presenting 40 cases of childhood ACT associated
with 31 cases of other types of cancer; mainly breast (n=5) and
stomach (n=5) [10]. In addition, in that previous study we
described that the maximal number of cancer cases per family
(excluding ACT) were 4 cases in two families and 2 cases in six
families in the parental side segregating the R337H mutation. In
contrast, in the present study the families carrying the R337H
mutation are more frequently associated with a larger number of
other tumor types, where 71.4% of the families with R337H (10/
14) present 4 or more cancer cases and 50% (7/14) are LFL
according to Birch et al. [16].
Does this association between CPC and other cancer cases
reflect a different genetic profile than between ACT and other
types of cancer? Interestingly, almost all patients (Table 2) without
cases of cancer in their families are alive (P,0.05, Fisher’s Exact
Test), which is consistent with a lower malignancy of these tumors
without the germline TP53 R337H mutation (CPC and Pp).
In younger children, skull flexibility to accommodate an
increased volume and the capacity of functional adaptation of
the immature nervous system often allow CPC to reach large
dimensions before being diagnosed, while older children tend to
have typical signs of intracranial hypertension [8]. These authors
have shown in their previous histopathologic analysis, and further
confirmed by the re-evaluation of all present cases, that these
tumors are characterized as either papillary or solid tumors
composed of columnar or anaplastic epithelium, with signs of
frank malignancy including marked nuclear pleomorphism,
frequent mitosis, increased nucleus/cytoplasm ratio, high cell
density, foci of necrosis and loss of demarcation between tumor
cells and the surrounding brain tissue. The neuropathologic
diagnosis can be sometimes difficult even with the help of
immunohistochemistry and electron microscopy. In contrast,
papillomas are benign tumors composed of proliferative cells
similar to the normal choroid plexus. All histopathologic criteria
proposed for malignancy [21] were found in all CPC of the present
series: a) obvious invasion of adjacent neural tissue, b) loss of
regular papillary architecture, c) marked nuclear pleomorphism, d)
Table 2. Survival and history of cancer in the families of children with CPC or Pp negative for the R337H mutation.
Patient
Gender/Age
(years) Treatment Outcome Histopathology
Blood DNA
R337H
Tumor DNA
R337H Family history of cancer
Side 1* Side 2
nn
15 F/9.2 CSR/Ct Deceased CPC Neg Neg 2 0
16 M/1.3 CSR/Ct Deceased CPC Neg Neg 2 1
17 M/4.9 CSR/Ct Deceased CPC Neg Neg 5 1
18 M/0.2 CSR/Ct Deceased CPC Neg Neg 2 0
19 F/3y CSR/Ct Deceased CPC Neg Neg 0 0
20 M/0.3 CSR/Ct Alive CPC Neg Neg 0 0
21 M/0.7 CSR/Ct Alive CPC Neg Neg 1 0
22 F/1.7 CSR/Ct Deceased CPC Neg Neg 0 0
23 M/5.8 CSR Alive Pp Neg Neg 2 1
24 F/0.7 CSR Deceased Pp Neg Neg 2 1
25 F/0.8 CSR Deceased Pp Neg Neg 3 1
26 F/9.8 CSR Alive Pp Neg Neg 0 0
27 F/1y CSR Alive Pp Neg Neg 0 NA
28 M/0.5 CSR Alive Pp Neg Neg 0 0
29 M/24 CSR Alive Pp Neg Neg 0 0
Total CPC (n=8)
Pp (n=7)
CPC (n=8)
Pp (n=7)
CPC (n=8)
Pp (n=7)
CPC (n=12)
Pp (n=7)
CPC (n=2)
Pp (n=3)
Survival rate** CPC = 2/8 (25%)
Pp = 4/6 (66.6%)
CSR, Complete surgical removal; Ct, Chemotherapy;
*Parental side with higher number of cancer cases;
**.5 years free of disease.
doi:10.1371/journal.pone.0018015.t002
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focal necrosis.
There may be some difficulty in the diagnosis of CPC due to
their morphologic characteristics, similar to those of other tumors
in routine microscopy, making it vital to find biologic markers to
characterize these tumors. The differential diagnosis must be made
with other neuroectodermal tumors, such as ependymomas,
metastatic papillary carcinomas (uncommon in children), embry-
onal carcinomas, anaplastic meningiomas, glioblastomas, and
malignant pituitary adenomas, among others [21,22]. Some
immunohistochemical markers are proposed, including glial acid
fibrillary protein (22–85%), S-100 protein (40–94%); vimentin
(16–88%), epithelial antigen membrane (69-71%), neuron-specific
enolase (20–100%), prealbumin (67–100%), carcinoembryonic
antigen (0–50%) and cytokeratin (83–100%) [23].
The mechanisms involved in CPC formation are not clear and
the reported causes are scarce. Previous reports suggested that
inactivation of hSNF5/INI-1 might play a special role in CPC
development [6]. Furthermore, it was recently reported that loss of
p53 function seems to be the most prevalent cause [7]. These
authors have found germline TP53 mutation in 50% of the cases
(32/64). They also have reported that two sequence variants known
to confer TP53 dysfunction—TP53 codon72 and MDM2
SNP309—coexist in the majority of TP53 wild-type CPC (92%)
and not in TP53-mutated CPC, which suggests a complementary
mechanism of TP53 dysfunction in the absence of a TP53 mutation.
CPC has also been associated with Simian Virus 40 (SV40), a
primate polyomavirus potentially oncogenic in rodents, suggested
by the identification of DNA sequences in 50% of the CPC cases
in children [24]. Interestingly, DNA tumor virus proteins,
including SV40, HPV E6, and the adenovirus protein E1B-55k
inactivate p53 via high-affinity protein-protein interaction [25]. In
addition, another epigenetic mechanism of p53 inactivation
mediated by a viral protein that silences p53-activated transcrip-
tion, irrespective of p53 phosphorylation and stabilization, was
recently reported [26]. These authors have demonstrated that the
adenovirus protein E4-ORF3 may target p53 promoters as part of
a general anti-viral transcriptional silencing program, without co-
localizing with p53. These viral proteins are important candidates
to be further investigated in all cases of CPC and Pp.
The treatment of choice for CPC is surgical resection of the
tumor block, a potentially curative procedure that may confer up
to 50% survival in the series with the best results [27].
Radiotherapy has been recommended to reduce the tumor before
surgery and to control it in cases of locally-invasive disease,
disseminated or recurrent [1]. However, only five CPC patients of
the present series were submitted to radiotherapy, and only three
of them survived (two negative and one positive for the R337H
mutation). Chemotherapy is presented as a valuable instrument to
be associated with surgical treatment. There is, however, no
consensus on the chemotherapy of choice because of the difficulty
in drawing up protocols in view of the rarity of the tumor [28].
It was shown that patients with CPC presenting low tumor total
structural variation (TSV) and absence of TP53 dysfunction have a
favorable prognosis and can be successfully treated without radiation
therapy [7]. In contrast, these authors have shown that high TSV was
associated with significant risk of progression and that five-year
survival rates for patients with TP53-immunopositive and immuno-
negative CPCs were 0% and 82%, respectively. They also have
shown that 14 of 16 patients with TP53 w i l d - t y p eC P Ca r ea l i v e
without having received radiation therapy. Survival rate (.5y e a r s
free of disease) in our present series was 18.1% (2/11) for R337H
positive CPC (Table 1) and 22% for R337H-negative CPC (Table 2).
This lower survival rate in R337H-negative CPC, in contrast to the
Canadian series (82%), may be due to differences in treatment
protocols, or delay in tumor diagnosis. Patients with germline TP53
mutations seem to be at a higher risk of secondary radio-induced
malignancies due to the risk of inducing new mutations in the wild-
copy of the gene [31,32]. Further studies are necessary to evaluate the
risk/benefit ratio of postoperative radiotherapy in long-term CPC
survivors carrying the germline R337H mutation.
In conclusion, the R337H TP53 mutation may be responsible
for an increased CPC incidence in Curitiba and probably in other
regions of southern Brazil, where the mutation was already
documented to be very frequent in ACT (around 85–95% in the
states of Sa ˜o Paulo and Parana ´) [9,11,29]. Further studies of TP53
mutations are necessary to understand their contribution to CPC
formation and their participation in CPC prognosis. It will be
necessary to continue identifying relatives positive for the R337H
mutation in order to provide genetic counseling and orientation
for precocious cancer diagnosis.
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